News

Dec
18
2018

Aristea Therapeutics Launches with Phase 2 Drug Candidate and $15M in Series A Funding from Novo Holdings A/S

SAN DIEGO, Dec. 18, 2018 /PRNewswire/ — Aristea Therapeutics (Aristea), a clinical-stage drug development company developing novel therapies to treat serious inflammatory diseases, today announced that it has secured $15M from Novo Holdings A/S (Novo Holdings) in a completed Series A financing. Aristea has also obtained exclusive global rights to its lead program RIST4721, from AstraZeneca. Aristea plans to initiate a Phase 2 clinical study in early 2019. In connection with the financing, Tiba Aynechi, Ph.D and Ken Harrison, Ph.D from Novo Ventures (US), Inc have been appointed to Aristea’s Board of Directors.